Journal of Feline Medicine and Surgery · 2015 · 26 citations · 18 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaTumor PathologyMalignant NeoplasmsOncogene MutationsActivating MutationsFeline Tumor PathologyMast Cell BiologyMast Cell DifferentiationMicroscopic CharacterizationProto-oncogene Mutation
OBJECTIVES: Feline intestinal mast cell tumours (FIMCTs) are rare and reportedly characterised by poor differentiation, aggressive biological behaviour and lack of reliable therapeutic aids. KIT proto-oncogene-activating mutations have never been investigated in these tumours. This study describes the main clinicopathological and microscopic features observed in 17 FIMCTs. METHODS: Tumour degree of differentiation, proliferative activity, Kit protein expression and KIT mutations were evaluated and correlated with survival to assess their prognostic relevance. RESULTS: Ten tumours were located in the small intestine, two in the ileocaecocolic junction, and five in the large intestine. Survival times ranged from 3-538 days. Fifteen tumours were evaluated histologically, and there were six well-differentiated, six moderately differentiated and three poorly differentiated FIMCTs. The last showed a medium-to-large deposition of collagen tissue (P <0.001), and significantly higher mitotic and Ki67 indexes compared with more differentiated tumours (P = 0.011). On survival analysis, tumour degree of differentiation (P <0.001) and a mitotic index >2 (P = 0.022) were significantly associated with decreased survival times. Twelve cases showed Kit protein immunoexpression. The Kit pattern was membranous in five cases (33.3%), focal paranuclear in five (33.3%) and diffuse cytoplasmic in two (13.3%). Cytoplasmic Kit patterns were associated with a lesser differentiation (P = 0.015). Mutation analysis was successfully performed on 12 primary tumours and four lymph node metastases; however, no encoding mutation was detected. CONCLUSIONS AND RELEVANCE: Contrary to reports in the literature, FIMCTs seem to have an extremely variable biological behaviour. We propose a classification based on tumour degree of differentiation and proliferative activity. These findings need to be confirmed in larger series, and exploration of further genomic regions of KIT is warranted to clarify its role in the development and progression of these neoplasms.
18
Cheryl A. London, Phyllis B. Malpas, Stacey L. Wood-Follis et al. · Clinical Cancer Research · 2009 · 422 citations · Full text
Medicine, Oncology, Pharmacology +15
Michele Columbo, Edward M. Horowitz, Luís M. Botana et al. · The Journal of Immunology · 1992 · 304 citations · Full text
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
K. Hahn, G. Oglivie, Todd Rusk et al. · Journal of Veterinary Internal Medicine · 2008 · 284 citations · Full text
The c-kit receptor ligand functions as a mast cell chemoattractant
CJ Meininger, Hajime Yano, Robert Rottapel et al. · Blood · 1992 · 280 citations · Full text
The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell Tumors
Joshua D. Webster, Vilma Yuzbasiyan‐Gurkan, John B. Kaneene et al. · Neoplasia · 2006 · 222 citations · Full text